Human Papillomavirus L1L2-E7 Virus-Like Particles Partially Mature Human Dendritic Cells and Elicit E7-Specific T-Helper Responses From Patients With Cervical Intraepithelial Neoplasia or Cervical Cancer In Vitro

Warrino, Dominic; Olson, Walter C.; Scarrow, Meera I.; D’Ambrosio-Brennan, Lori J.; Guido, Richard S.; Silva, Diane M. Da; Kast, W. Martin; Storkus, Walter J.

doi:10.1016/j.humimm.2005.04.006

Cited by 16 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results suggest that PapMV VLPs possess an intrinsic adjuvant-like property that induces DC maturation. Compared to other VLP-based systems, PapMV VLPs seem to be one of the more potent at inducing the upregulation of cosignaling molecules on DCs (15,18,40,41).…”

Section: Resultsmentioning

confidence: 99%

Novel Plant Virus-Based Vaccine Induces Protective Cytotoxic T-Lymphocyte-Mediated Antiviral Immunity through Dendritic Cell Maturation

Lacasse

Denis

Lapointe

et al. 2008

J Virol

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Novel Plant Virus-Based Vaccine Induces Protective Cytotoxic T-Lymphocyte-Mediated Antiviral Immunity through Dendritic Cell Maturation

Lacasse

Denis

Lapointe

et al. 2008

J Virol

View full text Add to dashboard Cite

“…It has been shown that the expression of L1 can lead to the formation of VLPs in eukaryotic cells [25]. Furthermore, previous studies have demonstrated that papillomavirus VLPs can directly activate dendritic cells and thereby increase expression of costimulatory markers and MHC class I and II molecules [26][27][28]. Thus, the co-administration of L1 DNA may lead to the local activation of DCs, resulting in further enhancement of antigen-specific CD8 + T cell immune responses generated by DNA vaccination.…”

Section: Discussionmentioning

confidence: 99%

Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination

Yang

Peng

et al. 2015

Cell Biosci

View full text Add to dashboard Cite

BackgroundDNA vaccines have emerged as attractive candidates for the control of human papillomavirus (HPV)-associated malignancies. However, DNA vaccines suffer from limited immunogenicity and thus strategies to enhance DNA vaccine potency are needed. We have previously demonstrated that for DNA vaccines encoding HPV-16 E7 antigen (CRT/E7) linkage with calreticulin (CRT) linked enhances both the E7-specific CD8+ T cell immune responses and antitumor effects against E7-expressing tumors. In the current study, we aim to introduce an approach to elicit potent CD4+ T cell help for the enhancement of antigen-specific CD8+ T cell immune responses generated by CRT/E7 DNA vaccination by using co-administration of a DNA vector expressing papillomavirus major and minor capsid antigens, L1 and L2.ResultWe showed that co-administration of vectors containing codon-optimized bovine papillomavirus type 1 (BPV-1) L1 and L2 in combination with DNA vaccines could elicit enhanced antigen-specific CD8+ in both CRT/E7 and ovalbumin (OVA) antigenic systems. We also demonstrated that co-administration of vectors expressing BPV-1 L1 and/or L2 DNA with CRT/E7 DNA led to the generation of L1/L2-specific CD4+ T cell immune responses and L1-specific neutralizing antibodies. Furthermore, we showed that co-administration with DNA encoding BPV1 L1 significantly enhances the therapeutic antitumor effects generated by CRT/E7 DNA vaccination. In addition, the observed enhancement of CD8+ T cell immune responses by DNA encoding L1 and L2 was also found to extend to HPV-16 L1/L2 system.ConclusionOur strategy elicits both potent neutralizing antibody and therapeutic responses and may potentially be extended to other antigenic systems beyond papillomavirus for the control of infection and/or cancer.

show abstract

“…In a large number of tumors, TGF-β pathway mutations result in resistance to growth inhibition and ultimately promote proliferation of tumor cells [62,63]. TGFβ is also able to dramatically inhibit anti-cancer immune responses [64].…”

Section: Barriers To Immunological Treatment Of Ocmentioning

confidence: 99%

Understanding the Cross-Talk between Ovarian Tumors and Immune Cells: Mechanisms for Effective Immunotherapies

Chiriva‐Internati

Mirandola

Kast

et al. 2011

International Reviews of Immunology

Self Cite

View full text Add to dashboard Cite

Despite decades of research, ovarian cancer remains a lethal disease. Recent studies have reported the critical role played by the immune system in controlling growth and spread of ovarian tumors. Accordingly, immunotherapy has been indicated as the most likely successful new approach in the treatment of the disease. Unfortunately, ovarian cancer triggers immune inhibitory mechanisms that hamper anti-tumor responses. Therefore, future immunotherapies should be able to overcome these obstacles. Here we review the basic mechanisms of tumor immune surveillance with a particular focus on ovarian cancer, and we discuss cutting-edge strategies to promote immune system eradication of ovarian tumors.

show abstract

Human Papillomavirus L1L2-E7 Virus-Like Particles Partially Mature Human Dendritic Cells and Elicit E7-Specific T-Helper Responses From Patients With Cervical Intraepithelial Neoplasia or Cervical Cancer In Vitro

Cited by 16 publications

References 30 publications

Novel Plant Virus-Based Vaccine Induces Protective Cytotoxic T-Lymphocyte-Mediated Antiviral Immunity through Dendritic Cell Maturation

Novel Plant Virus-Based Vaccine Induces Protective Cytotoxic T-Lymphocyte-Mediated Antiviral Immunity through Dendritic Cell Maturation

Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination

Understanding the Cross-Talk between Ovarian Tumors and Immune Cells: Mechanisms for Effective Immunotherapies

Contact Info

Product

Resources

About